Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

IF 3.3 3区医学 Q1 UROLOGY & NEPHROLOGY Journal of Sexual Medicine Pub Date : 2025-01-19 DOI:10.1093/jsxmed/qdae206

Olivia Copelan, Jared Moss, Sheldon Freedman, Karl Coutinho, Dean Elterman, Jeffrey Marotte, Osvaldo Padron, Neal Shore, Jeffrey Spier, Jed Kaminetsky, Brian Mazzarella, Alexis Te, Steven A Kaplan, Kevin T McVary

{"title":"Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.","authors":"Olivia Copelan, Jared Moss, Sheldon Freedman, Karl Coutinho, Dean Elterman, Jeffrey Marotte, Osvaldo Padron, Neal Shore, Jeffrey Spier, Jed Kaminetsky, Brian Mazzarella, Alexis Te, Steven A Kaplan, Kevin T McVary","doi":"10.1093/jsxmed/qdae206","DOIUrl":null,"url":null,"abstract":"Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.Aim: We now assess the impact of Optilume BPH procedure on sexual function.Methods: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms. Follow-up assessments for the current study included IIEF-EF and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD). Semen quality was also examined.Outcomes: IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3 months, 6 months, or 12 months.Results: A total of 148 men were randomized to receive the procedure (100) or a sham surgical procedure (48). Subjects in both groups had similar rates of erectile dysfunction (ED) previously diagnosed at baseline (56% vs 54.2%, P = .83) and those men who were sexually active. IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3, 6, or 12 months. Change in IIEF-EF scores remained consistent across all levels of baseline ED severity after Optilume BPH procedure. No clear trend was seen after treatment with Optilume BPH for semen volume, sperm motility, progressive motility, or sperm morphology.Clinical implications: The Optilume BPH catheter system provides patients with a durable improvement in lower urinary tract symptoms while preserving sexual function.Strengths and limitations: This study uses validated questionnaires to assess patients' sexual function at baseline and regularly for 1 year after the procedure. Given exclusion criteria regarding patient age and prostate size, the results may not be applicable to all BPH phenotypes.Conclusion: Optilume appears to provide clinical benefit with a high degree of patient satisfaction and minimal impact on sexual function.","PeriodicalId":51100,"journal":{"name":"Journal of Sexual Medicine","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jsxmed/qdae206","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms.

Aim: We now assess the impact of Optilume BPH procedure on sexual function.

Methods: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms. Follow-up assessments for the current study included IIEF-EF and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD). Semen quality was also examined.

Outcomes: IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3 months, 6 months, or 12 months.

Results: A total of 148 men were randomized to receive the procedure (100) or a sham surgical procedure (48). Subjects in both groups had similar rates of erectile dysfunction (ED) previously diagnosed at baseline (56% vs 54.2%, P = .83) and those men who were sexually active. IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3, 6, or 12 months. Change in IIEF-EF scores remained consistent across all levels of baseline ED severity after Optilume BPH procedure. No clear trend was seen after treatment with Optilume BPH for semen volume, sperm motility, progressive motility, or sperm morphology.

Clinical implications: The Optilume BPH catheter system provides patients with a durable improvement in lower urinary tract symptoms while preserving sexual function.

Strengths and limitations: This study uses validated questionnaires to assess patients' sexual function at baseline and regularly for 1 year after the procedure. Given exclusion criteria regarding patient age and prostate size, the results may not be applicable to all BPH phenotypes.

Conclusion: Optilume appears to provide clinical benefit with a high degree of patient satisfaction and minimal impact on sexual function.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

保存性功能的奥美美-一种治疗继发于良性前列腺增生的下尿路症状的新方法

背景：Optilume良性前列腺增生（BPH）导管系统是一种新型的微创紫杉醇包被扩张系统，在尿流和症状方面显示出实质性和持久的效果。目的：我们现在评估Optilume BPH手术对性功能的影响。方法：先前发表的结果描述了PINNACLE研究期间的数据收集方法，该研究证明了泌尿系统症状的持久改善。本研究的随访评估包括ief - ef和男性射精功能障碍性健康问卷（MSHQ-EjD）。还检查了精液质量。结果：Optilume BPH组的IIEF-EF和MSHQ-EjD评分在3个月、6个月和12个月时与假手术组没有差异。结果：共有148名男性随机接受手术（100人）或假手术（48人）。两组受试者在基线时被诊断为勃起功能障碍（ED）的比例相似（56%对54.2%,P = 0.83）。Optilume BPH组的IIEF-EF和MSHQ-EjD评分在3个月、6个月和12个月时与假手术组没有差异。在Optilume BPH手术后，IIEF-EF评分的变化在所有基线ED严重程度水平上保持一致。用Optilume治疗后，在精液量、精子活力、进行性活力或精子形态方面没有明显的变化趋势。临床意义：Optilume BPH导尿管系统为患者提供了持久的改善下尿路症状，同时保持性功能。优势和局限性：本研究使用有效的问卷来评估患者在基线时的性功能，并在手术后1年内定期评估。考虑到患者年龄和前列腺大小的排除标准，结果可能不适用于所有BPH表型。结论：opoplume具有临床疗效，患者满意度高，对性功能影响小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Sexual Medicine 医学-泌尿学与肾脏学

CiteScore

6.20

自引率

5.70%

发文量

826

审稿时长

2-4 weeks

期刊介绍： The Journal of Sexual Medicine publishes multidisciplinary basic science and clinical research to define and understand the scientific basis of male, female, and couples sexual function and dysfunction. As an official journal of the International Society for Sexual Medicine and the International Society for the Study of Women''s Sexual Health, it provides healthcare professionals in sexual medicine with essential educational content and promotes the exchange of scientific information generated from experimental and clinical research. The Journal of Sexual Medicine includes basic science and clinical research studies in the psychologic and biologic aspects of male, female, and couples sexual function and dysfunction, and highlights new observations and research, results with innovative treatments and all other topics relevant to clinical sexual medicine. The objective of The Journal of Sexual Medicine is to serve as an interdisciplinary forum to integrate the exchange among disciplines concerned with the whole field of human sexuality. The journal accomplishes this objective by publishing original articles, as well as other scientific and educational documents that support the mission of the International Society for Sexual Medicine.